

# Pediatric Radiotherapy in the 21<sup>st</sup> Century

John Breneman, MD  
Cincinnati Children's Hospital/University of Cincinnati



---

---

---

---

---

---

---

---

## Disclosures



- Senior Editor for pediatrics and sarcomas for the International Journal of Radiation Oncology Biology Physics (compensated)
- Chair of Peds/CNS written exam committee for the American Board of Radiology (non-compensated)
- Vice-chair of Radiation Oncology for the Children's Oncology Group (non-compensated)

---

---

---

---

---

---

---

---

## Outline



- Overview of radiotherapy in the treatment of pediatric cancer
- Strategies and examples of pediatric radiotherapy in the 21<sup>st</sup> century
  - Risk-adapted radiotherapy
  - Combined radiotherapy and systemic agents
  - Radiotherapy for metastatic disease
  - Protons

---

---

---

---

---

---

---

---

- Cancer is the second most common cause of death among children and adolescents in the United States, surpassed only by accidents
- Approximately 16,000 children and adolescents are diagnosed with cancer each year in the U.S.
- 2000 will die from their disease



CA: A Cancer Journal for Clinicians  
Volume 1, Issue 1, 2004, pp 1-10

---

---

---

---


---

---

---

---

- Between 1975 and 2004, 5 year mortality from pediatric cancers decreased from 42% to 20%




---

---

---

---

---

---

---

---

### The Role of Radiotherapy

- Although its use has declined over time, radiotherapy plays a significant role in the treatment of many of the common pediatric cancers

- CNS tumors
- Sarcomas
- Neuroblastoma
- Wilms tumor
- Hodgkin lymphoma
- TBI for transplants

About 1/3 of children with cancer get radiotherapy




---

---

---

---

---

---

---

---



But...

- Radiotherapy is a significant contributor to the morbidity of cancer treatment in children

---

---

---

---

---

---

---

---



- 18 Gy to the left hemi-thorax at age 11 for Ewing sarcoma



Courtesy of Lynn Millon, MD

---

---

---

---

---


---

---

---



- 55 Gy to left lower leg at age 8 for Ewing sarcoma



Courtesy of Lynn Millon, MD

---

---

---

---

---

---

---

---

Not all radiation late effects are visible 

- Neurocognition
- Neuroendocrine
- Functional
  - Pulmonary
  - Cardiac
  - Reproductive
- Risk of radiation-induced malignancy




---

---

---

---

---

---

---

---

Pediatric Radiotherapy Treatment and Research in the 21<sup>st</sup> Century 

- Maximize efficacy
- Minimize side effects
  - [Risk-adapted radiotherapy](#)
  - [Combined radiotherapy and systemic agents](#)
  - [Radiotherapy for metastatic disease](#)
  - [Protons](#)




---

---

---

---

---

---

---

---

Risk-adapted Radiotherapy 

- Modifying radiotherapy based upon [specific prognostic factors](#), or [response to other anti-neoplastic therapy](#)




---

---

---

---

---

---

---


---

### Risk Adaptation Based on Prognostic Factors

#### Medulloblastoma

• Old Classification

- Classic
- Desmoplastic
- Large Cell Anaplastic



"Average Risk"  
(23.4 Gy CSI)  
vs  
"High Risk"  
(36-39.6 Gy CSI)

**All Get CSI**

---

---

---

---



---

---

---

---

### Risk Adaptation Based on Prognostic Factors



---

---

---

---


---

---

---

---

### Response-adapted therapy



RESEARCH ARTICLE | WILEY | Pediatric Blood & Cancer | aspho  
**45 Gy is not sufficient radiotherapy dose for Group III orbital embryonal rhabdomyosarcoma after less than complete response to 12 weeks of ARST0331 chemotherapy**  
A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group

---

---

---

---

---

---

---

---

## Combined radiotherapy and systemic agents



- Radiosensitizers
- Biologic agents
- Immunotherapy

---

---

---

---

---

---

---

---



- Radiosensitizers
  - Chemical agents that are synergistic with radiation, increasing tumor cell kill
  - Most are cytotoxic chemotherapy drugs (poisons) that act on DNA causing damage and inhibiting DNA repair
  - The interaction/synergism between most cytotoxic agents and ionizing radiation has been well characterized

---

---

---


---

---

---

---

---



+



=

**Improved Survival**

---

---

---

---

---

---

---


---



### Biologic Agents (targeted therapy)

- Everolimus
- Dabrafenib
- Pazopanib
- etc

The interactions between ionizing radiotherapy and most biologic agents have **NOT** been well characterized




---

---

---

---

---

---


---

---

---

---

### Immunotherapy




---

---

---

---

---

---


---

---

---

---

### Abscopal Response of Un-irradiated Tumor




---

---

---

---

---

---

---

---

---

---

## Radiotherapy for metastatic disease



- Traditionally, treatment of metastatic disease has been almost entirely in the realm of chemotherapy
- Some exceptions
  - TBI for leukemia
  - Whole lung RT for Wilms tumor, Ewing sarcoma
- Radiotherapy for metastases is limited by toxicity

---

---

---


---

---

---

---

---



---

---

---

---


---

---

---

---

Risk of cardiac events increases non-linearly with increasing radiation dose



Van der Pijl et al. JCO, 2012

---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

**Radiotherapy for metastatic disease**



**Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial**

David A Palma, Robert Okun, Stephen Haxwou, Stewart Gaele, Alexander V Loebe, Cornelia Haackbeck, Liam Mulroy, Michael Lock, George B Rodrigues, Brian P Yamamoto, Devin Schellenberg, Bekal Ahmad, Guendalyn Griffiths, Sohanrao Serrhi, Anand Swaminath, Neil Kayek, Mitchell Liu, Karen Moore, Suzanne Cunniff, Glenn S Bauman, Andrew Warner, Sameek Senan

Lancet, 2018

---

---

---


---

---

---

---

---



---

---

---

---

---


---

---

---

- Stereotactic Body Radiotherapy (SBRT)

Metastasis from Ewing sarcoma



---

---

---

---


---

---

---

---

### Protons



---

---

---

---

---

---

---

---



- About 70% of children requiring radiotherapy would benefit from protons
  - Most brain tumors
  - Most sarcomas
  - Hodgkin lymphoma
  - Probably neuroblastoma
  - Possibly Wilms tumor

---

---

---


---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---

---

---

---

---

---



### Brain stem injury



---

---

---

---


---

---

---

---

### Dose vs LET/RBE



Pestler et al. 2016

---

---

---

---


---

---

---

---

### Cells Respond Differently to Proton/Carbon Particle Therapy vs X-ray/Photon Beams



---

---

---

---

---

---

---

---

So.....



- Pediatric radiotherapy in the 21<sup>st</sup> century will
  - **Increase efficacy** through combination with systemic agents, identifying high risk patients requiring RT, and new indications for RT such as oligometastases
  - **Decrease side effects** by better understanding of the biologic responses to RT (especially protons), identifying patients requiring less or no radiotherapy, and improving technology for radiotherapy targeting and delivery

---

---

---

---

---

---

---

---



---

---

---

---

---

---

---

---



---

---

---

---

---

---

---

---

**New Developments for Pediatric Radiotherapy –**  
**A Clinician's Wish List for Physics**



- LET and RBE based treatment planning for protons
- FLASH radiotherapy
- More "gentle" IGRT
- Standardized TBI
- "On the fly" adaptive treatment planning
- Improved algorithms/artificial intelligence to optimize treatment plans



---

---

---

---

---

---

---

---

On behalf of All the Children, thank you for your expertise and the role it plays in providing cures



---

---

---

---

---

---

---

---